PhOx430

Phost'In Therapeutics · Phase 1 active Small molecule

At a glance

Generic name	PhOx430
Also known as	Dose Escalation Phase - STEP 1 and STEP 2, Dose Escalation Phase - STEP 3 (Dosing-optimization Cohort)
Sponsor	Phost'In Therapeutics
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PhOx430 CI brief — competitive landscape report
PhOx430 updates RSS · CI watch RSS
Phost'In Therapeutics portfolio CI